Bi-directional signaling, or crosstalk, between the ER and epidermal growth factor receptor (EGFR)/HER2 signaling pathways, summarized in Fig. 1, has been implicated in tumor growth and survival as well as the development of resistance to ET in HR+/HER2+ tumors. Here, ESR1 is linked to neoplasm.